Glenmark Pharmaceuticals Limited has announced its unaudited financial results for the third quarter and nine months ended 31st December, 2025. The pharmaceutical company's Board of Directors approved these results at a meeting held on 30th January, 2026, which commenced at 04:30 p.m. and concluded at 06:40 p.m.

Strong Profitability Growth Led by PBT Performance

The company demonstrated exceptional profitability growth during Q3 FY26, with profit before tax (PBT) reaching ₹7.20 billion compared to ₹4.60 billion in the corresponding quarter of the previous year, representing a robust 57% year-on-year growth. This strong performance was complemented by EBITDA reaching ₹9.00 billion compared to ₹6.00 billion in Q3 FY25, marking a 50% increase.

Financial Performance Overview

The company delivered mixed performance across its standalone and consolidated operations during the third quarter of FY26. While consolidated revenue showed strong growth and profitability metrics were impressive, net profit fell short of analyst expectations.

Consolidated Results

The consolidated net profit of ₹4.00 billion, while showing year-over-year growth from ₹3.50 billion, significantly missed analyst estimates of ₹6.30 billion. However, revenue performance remained robust at ₹39.00 billion compared to ₹33.00 billion in the previous year.

Standalone Results

Exceptional Items Impact

The results included significant exceptional items totaling ₹1.84 billion that affected the company's performance. The company recognized ₹1,778.91 million in consolidated results and ₹1,770.73 million in standalone results towards employee benefits during Q3 FY26, following the Government of India's consolidation of multiple existing labour legislations into four unified Labour Codes effective 21st November, 2025.

Nine Months Performance

For the nine months ended 31st December, 2025, consolidated revenue from operations reached ₹1,32,119.25 million compared to ₹1,00,655.33 million in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹10,606.33 million versus ₹10,427.58 million in the previous year.

Operational Highlights

The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI regulations. The company's statutory auditors, Walker Chandiok & Co LLP, conducted a limited review and issued an unmodified report.

Glenmark Pharmaceuticals Limited has announced its quarterly earnings call to discuss Q3FY26 financial results, scheduled for Monday, February 02, 2026. The pharmaceutical company has formally notified stock exchanges BSE and NSE about this investor communication event under regulatory compliance requirements.

Earnings Call Schedule and Access Details

The Q3FY26 results discussion will be conducted as a conference call with specific timing and access arrangements for investors and analysts.

Global Dial-in Access Numbers

The company has provided multiple international access numbers to accommodate global investor participation:

Registration and Contact Information

Participants can pre-register online through the company's designated registration portal. For any clarifications regarding the earnings call, investors can contact Utkarsh Gandhi at utkarsh.gandhi3@glenmarkpharma.com or phone +91 22 4018 9232.

Regulatory Compliance and Recording

The earnings call announcement was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Harish Kuber signed the official communication to both stock exchanges on January 22, 2026. The company has confirmed that the complete recording of the earnings call will be available on its official website within 24 hours of the call's completion, ensuring accessibility for stakeholders who cannot participate in the live session.